How long does 3,4-CTMP last?

The total duration of 3,4-CTMP via oral is 6 hours to 18 hours. Onset typically occurs within 1 hour to 2 hours.

3,4-CTMP — SubstanceWiki

3,4-CTMP (3,4-dichloromethylphenidate; also written 3,4-DCMP) is a synthetic stimulant in the substituted phenidate class, a structural derivative of methylphenidate (Ritalin) with dichlorine substitution at the 3 and 4 positions of the phenyl ring. It is among the most potent and dangerous novel stimulants to appear in the research chemical market, characterized by a combination of extreme potency-to-dose ratio, unusually long duration (6–12 hours), high addiction potential, and narrow therapeutic-to-toxic margin.

3,4-CTMP emerged in UK and European markets around 2013–2015. Reports of hospitalizations and suspected fatalities, along with a pattern of compulsive use and difficulty stopping, led to rapid emergency scheduling in multiple jurisdictions. The compound exemplifies a class of research chemicals where the initial pharmacological novelty attracted users, but the unfamiliar risk profile — particularly the dramatically higher potency than expected from the dose — led to severe adverse events before the community had developed adequate harm-reduction knowledge. The serotonergic activity of 3,4-CTMP, which is unusual among phenidates, adds to its complexity and risk.

How It Feels

The onset of 3,4-CTMP is measured and deliberate. Forty-five minutes to an hour after oral ingestion, a steady current of wakefulness begins to build. The mind clears incrementally, attention becomes more adhesive, and there is a gradual awareness that the usual mental friction, the small resistances that make starting tasks effortful, has been quietly reduced. The body registers a mild increase in heart rate and a subtle tension in the muscles, but these are gentle accompaniments to a primarily cognitive shift.

As the effects develop over the following hour, 3,4-CTMP settles into a sustained, functional plateau. Focus deepens into something reliable and consistent. Tasks that require sustained attention become more approachable, and the mind stays on track without the constant redirection that characterizes normal cognitive wandering. The stimulation is clean but somewhat colorless, there is alertness and capability but little warmth or pleasure. Mood is neutral to mildly positive. Conversations are lucid but lack the animated quality that more euphoric stimulants bring. The body feels awake and slightly tense, with reduced appetite and a mild dryness in the mouth.

At the peak, roughly two to three hours in, the defining characteristic of 3,4-CTMP is its longevity rather than its intensity. The stimulation is moderate but it persists with a stubbornness that exceeds most compounds in its class. Hours pass with a uniform quality of alert productivity. There is no euphoric crest followed by a valley, just a long, flat mesa of enhanced function. The physical side effects, elevated heart rate, vasoconstriction, appetite suppression, maintain the same steady intensity throughout, which can become wearing over the extended duration.

The offset is where the compound's character becomes most apparent. The active effects can persist for ten to fourteen hours, and the taper is exceptionally slow. Long after you would like the stimulation to end, a residual wakefulness clings on, making sleep elusive. There is no dramatic crash, but the sheer duration can leave the user feeling worn and depleted by the time baseline finally returns. Restlessness, irritability, and difficulty sleeping may extend well into the night or even the following day. The lesson of 3,4-CTMP is one of patience: it arrives without drama and leaves on its own protracted schedule.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(9)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Tinnitus— Phantom perception of ringing, buzzing, or hissing in the ears without external sound source, potent...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(4)

Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...

Cognitive

Detection Methods

Standard Drug Panel Inclusion

3,4-CTMP (3,4-Dichloromethylphenidate) is a phenidate-class stimulant that is not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. Phenidates are structurally distinct from amphetamines and do not cross-react with amphetamine or methamphetamine antibodies used in commercial immunoassays. There is no dedicated phenidate channel on any standard workplace or clinical drug panel.

Urine Detection

3,4-CTMP (3,4-Dichloromethylphenidate) and its primary metabolite ritalinic acid (or the corresponding deesterified acid analogue) can be detected in urine for approximately 1 to 3 days after a single oral dose. The ester bond in phenidate compounds is rapidly hydrolyzed by plasma and hepatic esterases, producing the corresponding acid metabolite which is the dominant species found in urine. Higher doses or repeated administration may extend the detection window modestly.

Blood and Saliva Detection

Blood concentrations of 3,4-CTMP (3,4-Dichloromethylphenidate) decline rapidly due to ester hydrolysis, with a detection window of approximately 6 to 24 hours for the parent compound. The acid metabolite persists longer in plasma, detectable for up to 48 hours. Oral fluid testing can detect the parent compound for approximately 12 to 36 hours, though this route of detection is rarely employed for phenidates in practice.

Hair Follicle Detection

Hair follicle analysis may detect 3,4-CTMP (3,4-Dichloromethylphenidate) or its metabolites for up to 90 days. However, incorporation of phenidate-class compounds into hair has not been extensively studied, and commercial laboratories do not routinely test for these substances. Specialized forensic laboratories with LC-MS/MS capability and appropriate reference standards would be required.

Confirmatory Testing

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for confirming the presence of 3,4-CTMP (3,4-Dichloromethylphenidate) and its metabolites. The ester bond in phenidates makes them somewhat labile under GC-MS conditions, so LC-MS/MS is preferred. Both parent compound and the deesterified acid metabolite should be targeted for comprehensive analysis.

Reagent Testing

Marquis reagent typically shows no reaction or a very faint color change with 3,4-CTMP (3,4-Dichloromethylphenidate), which helps distinguish it from amphetamines (orange-brown) and MDMA (purple-black). Mecke reagent generally shows no reaction. Mandelin reagent may produce a faint yellow or no change. The absence of strong reagent reactions is characteristic of the phenidate class and is itself a useful piece of information when combined with other reagent results.

Interactions

Substance	Status	Note
25x-NBOH	Dangerous	—
25x-NBOMe	Dangerous	—
Atropa belladonna	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Datura	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Diphenhydramine	Dangerous	Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Harmala alkaloid	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Peganum harmala	Dangerous	Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
MDMA	Unsafe	—
1,3-Butanediol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
25E-NBOH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-2	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-21	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-T-7	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increased cardiovascular strain and neurotoxicity risk
4-MMC	Caution	Increased cardiovascular strain and neurotoxicity risk
8-Chlorotheophylline	Caution	Increased cardiovascular strain and neurotoxicity risk
Adrafinil	Caution	Increased cardiovascular strain and neurotoxicity risk
Allylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ayahuasca	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Benzydamine	Caution	Increased cardiovascular strain and neurotoxicity risk
Bromantane	Caution	Increased cardiovascular strain and neurotoxicity risk
Cake	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Deschloroetizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Desomorphine	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
DET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increased cardiovascular strain and neurotoxicity risk
Diclazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
DiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DOM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
DPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Efavirenz	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephedrine	Caution	Increased cardiovascular strain and neurotoxicity risk
EPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Eszopiclone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Etizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flubromazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Flunitrazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Gaboxadol	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Hexedrone	Caution	Increased cardiovascular strain and neurotoxicity risk
Ibogaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lorazepam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Mephenaqualone	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MET	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methallylescaline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increased cardiovascular strain and neurotoxicity risk
Metizolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Midazolam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
MiPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MPT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Naloxone	Caution	Stimulants mask opioid sedation, increasing overdose risk when the stimulant wears off
Nicotine	Caution	Increased cardiovascular strain and neurotoxicity risk
Nifoxipam	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Oxiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Pentobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenobarbital	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Phenylpiracetam	Caution	Increased cardiovascular strain and neurotoxicity risk
Psilocybin Mushrooms	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increased cardiovascular strain and neurotoxicity risk
SAMe	Caution	Masks the effects of each drug; risk of overdosing when one wears off before the other
Alcohol	Uncertain	—

Showing 63 key interactions out of 64 total.

Toxicity & Safety

Documented Harm

3,4-CTMP has been associated with hospitalizations and suspected deaths — a documented harm profile that distinguishes it from most research chemical stimulants. Adverse events include cardiovascular complications, apparent overdose, and complications from compulsive redosing and prolonged use. The exact mechanism of the most severe reported cases is not always clear, but the combination of high potency, long duration, and serotonergic activity is implicated.

Cardiovascular Toxicity

Potent dopamine and norepinephrine reuptake inhibition produces significant cardiovascular stimulation — tachycardia, hypertension, vasoconstriction — sustained over 6–12 hours. The prolonged nature of this cardiovascular burden substantially increases risk compared to short-acting stimulants, particularly in the context of multiple redoses.

Addiction and Compulsive Use

The extended potent dopaminergic stimulation produces strong positive reinforcement, and the duration of action extends the "binge window." Reports of compulsive redosing, inability to stop, prolonged wakefulness, and severe withdrawal are common in user accounts. The addiction and dependence liability appears disproportionately high relative to other phenidate class stimulants.

Serotonin Syndrome Risk

The unusual SERT activity means 3,4-CTMP should not be combined with MAOIs, SSRIs, or other serotonergic drugs — a contraindication not typically associated with phenidate class stimulants.

Severe Contraindications

MAOIs — serotonin syndrome risk
Cardiovascular disease, hypertension, arrhythmias
History of stimulant addiction or psychosis
Any concurrent stimulant medication

Overdose Information

fatal heart disease when used for even relatively short periods of time. It is highly recommended that, should one choose to use this substance despite these concerns, it only be taken very sparingly and in low doses. Those with cardiovascular diseases of any kind should not consume this substance. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Extreme caution must be taken when managing one's 3,4-CTMP usage as the duration of its stimulating effects can be very long, which can cause unwanted sleep inhibition. This should be considered when redosing as the physically stimulating effects of a dose may persist after the psychological effects have worn off. A user attempting to maintain a state of euphoria may run the risk of accumulating medically dangerous quantities of the substance in their bloodstream.

It is strongly recommended that one not insufflate 3,4-CTMP as it has a low solubility in water so is not readily absorbed through the nasal mucus membrane and anecdotal reports suggest that insufflation of the substance is painful and potentially extremely caustic. Additionally, the poor adsorption by the nasal mucus membrane often results in the majority of the substance slowly entering the stomach through a post-nasal drip, making the onset duration even longer, which may increase the chance of an 'accidental overdose' if one redoses more due to a lack of effect.

It is strongly recommended that one use harm reduction practices when choosing to use this substance.

In terms of its tolerance, many users have reported that 3,4-CTMP can be used for multiple days in a row for extended periods of time without any noticeable acute tolerance build up, instead increasing gradually over regular and extended use. Unusually, there are some reports indicating a sudden rise in tolerance after an extended period of relatively little increase. This results in the user

Full	Unknown
Half	Unknown
Zero	Unknown

3,4-CTMP

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(9)

Tactile(1)

Cognitive & Perceptual Effects

Visual(4)

Cognitive

Pharmacology

Mechanism of Action

Potency Context

Pharmacokinetics

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Saliva Detection

Hair Follicle Detection

Confirmatory Testing

Reagent Testing

Interactions

History

Emergence and Rapid Scheduling

Significance as a Harm Case

Legal Status

Harm Reduction

Critical Warning: Disproportionate Potency

Dose Guidelines

Duration Planning

Addiction Risk Management

Seek Emergency Care

Toxicity & Safety

Documented Harm

Cardiovascular Toxicity

Addiction and Compulsive Use

Serotonin Syndrome Risk

Severe Contraindications

Overdose Information

Dangerous Interactions

Tolerance

Legal Status

Experience Reports (2)

Tips (4)

See Also

References (3)

Frequently Asked Questions